GLP-1 Market Intelligence: Tirzepatide Projected as World's Top-Selling Drug in 2026

Combined GLP-1 revenue is projected to exceed $84 billion in 2026. Tirzepatide overtakes semaglutide as the world's top-selling drug. 18% of US adults have tried a GLP-1. Complete market intelligence report with pipeline analysis.

The numbers tell a story that even insiders didn't predict five years ago. According to Evaluate's 2026 Preview report, tirzepatide is projected to be the top-selling drug in the world in 2026 — not just in the obesity or diabetes categories, but across all pharmaceutical products globally.

The $84.5 Billion GLP-1 Market

Combined projected 2026 revenue for the two dominant GLP-1 molecules:

Breaking down the brand-level projections:

Lilly's tirzepatide franchise ($45.5B combined) overtakes Novo's semaglutide franchise ($34.8B) for the first time — a position swap driven by Zepbound's obesity indication growth and Mounjaro's T2D market dominance.

Adoption Curve: Who's Taking GLP-1s?

KFF survey data from November 2025 provides the clearest picture of US adoption rates:

• 18% of US adults have tried a GLP-1 medication
• 12% are currently taking one
• 43% of diagnosed obese/overweight adults not currently using GLP-1s are interested in starting
• 27% of diagnosed diabetic or heart disease patients are interested

The 43% interest rate among unmedicated obese adults represents an enormous addressable market. At current pricing, cost remains the primary barrier — which is why the compounded and generic oral markets are growing as fast as brand-name sales.

The Indication Expansion Engine

GLP-1s are no longer "weight loss drugs." The 2025–2026 indication expansion cycle is reshaping the clinical positioning of the entire class:

• Cardiovascular disease: Wegovy CVOT (SELECT trial) positive; semaglutide now indicated for MACE risk reduction in adults with established CVD and obesity
• Sleep apnea: Zepbound FDA-approved for moderate-to-severe OSA (December 2024)
• Kidney disease: FLOW trial (semaglutide) showed 24% reduction in kidney disease progression
• MASLD/NASH: Multiple Phase 3 trials underway for semaglutide, tirzepatide, and survodutide
• Alcohol use disorder: JAMA Psychiatry data showing significant craving reduction
• Knee osteoarthritis: TRIUMPH-4 (retatrutide) showed 75.8% pain reduction

Each new indication expands the addressable patient population and payer coverage landscape. The ADA position that GLP-1s are first-line pharmacotherapy for T2D with cardiovascular risk has fundamentally changed prescribing patterns.

Competitive Pipeline: What's Next

The GLP-1 competitive landscape in 2026 includes several compounds that could shift market dynamics:

• Retatrutide (Eli Lilly): Triple agonist. TRIUMPH-1 just reported 28.3% weight loss. NDA submission expected late 2026/early 2027.
• Orforglipron (Eli Lilly): Oral GLP-1 pill (Foundayo). Already FDA-approved. Daily dosing, ~15% weight loss in trials.
• CagriSema (Novo Nordisk): Semaglutide + cagrilintide (amylin analog) combination. Phase 3 results expected 2026, targeting ~25% weight loss.
• Survodutide (Boehringer Ingelheim): GLP-1/glucagon dual agonist. Phase 3 data expected 2026.
• Amycretin (Novo Nordisk): Oral GLP-1/amylin co-agonist. Phase 2 showed ~13% weight loss at 12 weeks — the fastest oral weight loss kinetics reported to date.

The Compounding Market Variable

One factor that revenue projections don't fully capture: the compounded GLP-1 market. With compounded semaglutide available from $99–200/month versus $1,000+/month for brand-name Wegovy, a significant percentage of patients are using compounded versions — especially those without insurance coverage. FDA enforcement actions against some compounders in early 2026 have tightened the market, but legitimate 503A/503B pharmacies continue to operate legally.

The scale of the compounded market is difficult to quantify, but telehealth providers report compounded semaglutide as their highest-volume product category in 2025–2026.